NASDAQ · EVO
Healthcare · Drug Manufacturers - Specialty & Generic
$1.63
Down-$0.05 (-2.98%)
Updated Sep 16, 2026, 9:00 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
EVO closed at $1.63 after 20 trading sessions, down 14.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.62 | $1.6499 | $1.60 | $1.63 | 102.17K |
| Sep 14, 2026 | $1.68 | $1.69 | $1.66 | $1.68 | 37.7K |
| Sep 11, 2026 | $1.73 | $1.76 | $1.72 | $1.73 | 42.52K |
| Sep 10, 2026 | $1.77 | $1.77 | $1.7383 | $1.77 | 24K |
| Sep 9, 2026 | $1.83 | $1.83 | $1.805 | $1.81 | 43.75K |
| Sep 8, 2026 | $1.83 | $1.83 | $1.80 | $1.82 | 64.21K |
| Sep 4, 2026 | $1.86 | $1.86 | $1.8389 | $1.86 | 121.91K |
| Sep 3, 2026 | $1.95 | $1.95 | $1.89 | $1.90 | 94.28K |
| Sep 2, 2026 | $1.88 | $1.93 | $1.88 | $1.90 | 48.22K |
| Sep 1, 2026 | $1.85 | $1.855 | $1.80 | $1.80 | 38.41K |
| Aug 31, 2026 | $1.88 | $1.89 | $1.86 | $1.88 | 65.94K |
| Aug 28, 2026 | $1.95 | $1.95 | $1.905 | $1.91 | 28.22K |
| Aug 27, 2026 | $1.95 | $1.97 | $1.95 | $1.97 | 31.28K |
| Aug 26, 2026 | $1.95 | $1.955 | $1.93 | $1.95 | 31.08K |
| Aug 25, 2026 | $1.88 | $1.90 | $1.87 | $1.89 | 25.34K |
| Aug 24, 2026 | $1.92 | $1.92 | $1.89 | $1.89 | 22.65K |
| Aug 21, 2026 | $1.9191 | $1.95 | $1.915 | $1.93 | 40.87K |
| Aug 20, 2026 | $1.95 | $1.96 | $1.915 | $1.96 | 79.22K |
| Aug 19, 2026 | $1.90 | $1.98 | $1.90 | $1.98 | 34.91K |
| Aug 18, 2026 | $1.93 | $1.94 | $1.89 | $1.91 | 21.86K |
The latest Smart Investors Daily articles mentioning EVO.
EVO research
Company profile and research snapshot.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 29, 2026 | TD COWEN | Buy | — |
| Jun 28, 2026 | PORTZAMPARC BNP PARIBAS | Buy | — |
| May 17, 2026 | BERENBERG | Buy | — |
| May 6, 2026 | EQUI.TS | Neutral | — |
| Feb 4, 2026 | BERENBERG | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.
Benzinga · Sep 9, 2026
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures
Yahoo · Sep 2, 2026
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY® technology with Evotec's proprietary BiTco platform.
Benzinga · Aug 13, 2026
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.06) by 150 percent. This is a 15.38 percent decrease over losses of $(0.14) per share from the same
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EVO.
